結核菌群リファンピシン耐性遺伝子同定キット
Contents
1. 4 RFP 2007 20104E 0H BACTEC MGIT960 KY2. PCR LiPA Rif TBJ 2 2007 REP HiPA KEO
3. 753 LiPA 750 LIPA C PCR 4 746 NaOH MGIT 750 TB PNBA
4. BACTEC MGIT960 AST MGIT AST RFP INH REP S v LiPA EER Uc EME DS AL GB MTB 1 MIC LiPA DNA Rif TB 1 50 DNA 20 2 PCR NS 4800 Ice 7 op RFP Kim
5. 0 8 56 6 920 20 40 MDR TB 2002 n 591 8555 1180 TEL 072 252 3021 FAX 072 251 1372 E mail dustin kch hosp go jp 42 Vol 22 No 1 2012 C RD rpoB Line probe assay MDR TB 0 7 9 8 1 9 60 3 122 2009 MDR TB 940 3 3 WHO
6. 2 LiPA Jj LiPA S5 AS5 R4a R4b S4 S5 DNA 2 LiPA
7. ME 5 CGACCACTTCGGCAACCG 3 MR 5 TC GATCGGGCACATCCGG 37 hot spot 81bp 306 bp rpoB 3 500 Genetic Ana lyzer Applied Biosystems Blast UM Vol 22 No 1 2012 43 44 LiPA 750 50 Z LiPA Table 1 LiPA 750 33 LiPA MGIT AST REP 27 MGIT AST REFP INH MDR TB 6 MGIT_ AST RFP S 715 LiPA RFP MGIT AST REP INH 2 LiPA
8. LiPA 4 LiPA T RFP unknown MDR TB RFP WHO REP 3 LiPA MDR TB
9. BSS 1 550 MGIT AST C REP 6 0 4 750 LiPA REP 100 715 715 REP 94 3 33 35 LiPA MDR TB27 REP Vol 22 No 1 2012 45 46 MDR TB RFP conflict of interest Q007 20104E 1 550 MDR TB 58 X B 3 796 REP
10. MDR TB L 4 6 LiPA 43 MDR TB 2 MIC
11. hot spot hot spot LiPXW E 5 S1 S5 4 R2 R4a R4b R5 RFP Lieb EXHI 5 offigouB Ekca0 LiPA LiPA LiPA 2 genetic heterogeneity 2
12. RFP 1 2010 2010 64 4 1 LiPA RFP 4 7 35 750 2 Tuberculosis Research Committee Ryoken 2007 HiPA Drug resistant Mycobacterium tuberculosis in Japan MDR TB RFP A nationwide survey 2002 Int J Tuberc Lung Dis 11 1129 1135 0997 3 World Health Organization 2010 Global tuberculo 1999 LiPA sis control report 2010 World health organization RFP Genova Ser 531 54 496 His 526 7 896 Asp 516 10 796 4 Cavusoglu C S Hilmioglu S Guneri et al 2002 3 9 hot spot Characterization of rpoB mutations in rifampin RFP resistant clinical isolates of Mycobacterium tubercu 531 62 9 526 50 23
13. AS1 LiPA Table 3 Bartfai 513 Gln Lys 1 AS1 E REP fit E SHAK O RNA ERER BU 7 m b 7 op Results of LiPA compared with culture in detecting MTBC in primary clinical specimens Clinical specimen No of specimens LiPA pattern s No of specimens Sputum 700 S 668 AS1 3 AS4 AS5 2 R2 1 R4b 2 R5 20 Gastric aspirate 26 S 25 R4b 1 BAL 10 S 9 R5 1 Abscess 4 S 3 R5 1 Pleural fluid 2 S 2 Biopsy specimens 5 S 5 Urine 3 S 3 Total 750 MTBC excludes 3 specimens containing substances inhibitory to the polymerase chain reaction PCR or PCR equivocal results by LiPA LiPA line probe assay MTBC Mycobacterium tuberculosis complex Biopsy specimens obtained from miscellaneous sites including lung lymph node and pleura Table2 Performance of LiPA compared with the MGIT AST as a reference method for 750 M tuberculosis strains No of isolates with the following MGIT AST result LiPA re
14. 315 Evaluation of the INNO LiPA Rif TB assay a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resist T LIPA REP ance to rifampin Antimicrob Agents Chemother BUE OUR C INTEL HERS 5 5 A CHIC 41 2093 2098 8 Tortoli E F Marcelli 2007 Use of the INNO LiPA Rif TB for detection of Mycobacterium tuberculosis 5 DNA directly in clinical specimens and for simulta 4 LiPA neous determination of rifampin susceptibility Eur RFP J Clin Microbiol Infect Dis 26 51 55 9 2010 Line Probe Assay Rifampicin ER RARR EYL TORET 85 703 709 10 Wobeser W L M Krajden J Conly et al 19
15. RFP 27 MDR TB LiPA MDR TB 77 1 27 35 MDR TB 100 MDR TB E NE und s m RA Key words 2009 24 000 TERES 10 FY 19 0 2
16. Matsiota Bernard P G Vrioni E Marinis 1998 18 19 20 21 22 23 Characterization of rpoB mutations in rifampin resistant clinical Mycobacterium tuberculosis isolates from Greece J Clin Microbiol 36 20 23 The World Health Organization 2008 WHO IUATLD Global project on anti tuberculosis drug resistance surveillance Anti tuberculosis drug resis tance in the world Report No 4 WHO HTM TB 2008 394 Annex 1 f 2000 Line Probe Assay LIPA 75 573 581 Gagneux S C D Long P M Small et al 2006 The Competitive Cost of Antibiotic Resistance in Myco bacterium tuberculosis Science 312 1944 1946 Gagneux S 2009 Fitness cost of drug resistance in Mycobacterium tuberculosis Clin Microbiol Infect 15 66 68 2007 SEVERE C OLDER 82 531 538 Iwamoto T S Yoshida K Suzuki et al 2009 Pop ulation structure analysis of the Mycobacterium tu 2 berculosis Beijing family indicates an association between certain sublineages and multidrug resist ance Antimicrob Agents Chemother 52 3805 3809 Comprehensive Evaluation of a Line Probe Assay Kit for R
17. REP MGIT AST RFP INH amp 2 1 103 S RFP INH 1 71 S RFP INH 2 MIC JR RFP 0 06 0 5 ug ml INH 0 125 ug ml Table 2 71 SH SBS S Table 1 MIC RFP rpoB 71 103 9511 533 REP M MERE HC HS Z EERS tre LiPA REP 33 LiPA 2 511 526 526 His Leu AS4 1 648 AS4 761 513 O Gln ZH Alg AS1 526 His Pro AS4
18. 42 2012 RifTB Dh TEL A RL REAR IO 4 ARRA 23 8 3 23 12 24 Rif TB Line probe assay LiPA REP 753 LiPA 750 LiPA LiPA RFP 2715 715 35 35 33 MGIT AST RFP 6
19. 8 6 96 losis from Turkey by DNA sequencing and line probe 516 hot spot 0 assay J Clin Microbiol 40 4435 4438 5 Cooksey R C G P Morlock S Glickman et al 1997 Evaluation of a line probe assay kit for charac PIR Pa SE ORAM O MA a 5 terization of rpoB mutations in rifampin resistant Mycobacterium tuberculosis isolates from New York City J Clin Microbiol 35 1281 1283 SAM EEATAS CHAI RFP O rpoB 6 Hirano K C Abe M Takahashi 1999 Mutations F 75310 JEU INH fit TE JE ot AY fs BA DS Oz 33 0 2 of rpoB gene of rifampin resistant Mycobacterium kzfC 315 tuberculosis strains isolated mostly in Asian coun AVUAYyBRASOALBORKUCZSCAS uv tries and their rapid detection by line probe assay J 80 Clin Microbiol 37 2663 2666 2 MDR_ TB rpoB a F 75310 7 Rossau R H Traore H de Beenhouwer et al 1997 Agz7C
20. 96 46 Vol 22 No 1 2012 LIPA 47 11 12 13 14 15 16 17 Evaluation of Roche Amplicor PCR assay for Myco bacterium tuberculosis J Clin Microbiol 34 134 139 Bergmann J S G L Woods 1996 Clinical evalua tion of the Roche AMPLICOR PCR Mycobacterium tuberculosis test for detection of M tuberculosis in respiratory specimens J Clin Microbiol 34 1083 1085 f 2011 PNB iE PNBA 60 97 100 Kim B J S H Lee M A Lyu et al 1999 Identifi cation of mycobacterial species by comparative Se quence analysis of the RNA polymerase gene rpoB J Clin Microbiol 37 1714 1720 Jin D J C A Gross 1988 Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance J Mol Biol 5 45 58 B rtfai Z A Somosk vi C K dm n et al 2001 Molecular characterization of rifampin resistant iso lates of Mycobacterium tuberculosis from Hungary by DNA sequencing and the line probe assay J Clin Microbiol 39 3736 3739 Musser J M 1995 Antimicrobial agent resistance in mycobacteria Molecular genetic insights Clin Mi crobial Rev 8 496 514
21. apid Detection of Rifampicin Resistant Mycobacterium tuberculosis Clinical Performance and Inference of Infection Occurrences Shiomi Yoshida Motohisa Tomita Mika Kihara Hiroyuki Kikkawa P Clinical Research Center Department of Clinical Laboratory National Hospital Organization Kinki chuo Chest Medical Center 1180 Nagasone cho Kita ku Sakai Osaka 591 8555 Corresponding author Department of Clinical Laboratory National Hospital Organization Toneyama Hospital 5 1 1 Toneyama Toyonaka Osaka 560 8552 We evaluated a line probe assay LiPA kit which was designed to identify Mycobacterium tuberculosis complex and to detect mutations related to resistance to rifampicin for rapid detection of MDR TB A total of 750 clinical specimens from pulmonary and extrapulmonary sites were tested with LiPA directly and drug susceptibility testing Sequence in rpoB gene was also performed to 27 clinical isolates with both isoniazid and rifampicin resistance and the LiPA could detect rifampicin resistant TB in 35 specimens Compared with results of LiPA drug susceptibility testing and rpoB se quence several discordant results were observed in 2 rifampicin mono resistance TB strains and 2 MDR TB strains with Vol 22 No 1 2012 47 48 rpoB mutations The LiPA was more than just useful for the detection of MDR TB from variable clinical specimens al though t
22. he LiPA caused rare nonspecific reactions as the appropriate situations or correct operations It may provide clinical managements and summarize the evidence of molecular epidemiology of rifampicin resistant TB 48 Vol 22 No 1 2012
23. sult Susceptible Resistance Wild 0 Mutation 33 Drug concentrations 1 0 ug ml for RFP gt One isolate 71 was susceptible but other isolate 103 was resistance by proportion method based Ogawa egg medium Welpak S in Table 3 44 Vol 22 No 1 2012 LiPA 45 Table3 Discordant results of MTBC isolates by the susceptibility LiPA and DNA sequencing of the 306 bp region of the rpoB gene Drug susceptibility testing MGIT AST sample LiPA pattern RpoB mutation s Allele Amino acid change specimens Rifampicin Isoniazid 71 Susceptible Susceptible AS1 511 ctg gt ccg Leu Pro 103 Susceptible Susceptible AS5 533 ctg gt ccg Leu gt Pro 648 Resistance Resistance AS4 511 deletion Leu 526 cac ctc His Leu 761 Resistance Resistance AS1 513 caa cga Gln gt Arg 526 cac ccc His gt Pro Susceptible by MGIT AST and proportion method of Ogawa egg medium Welpak S but the MIC of 2 single colonies from the isolate showed 0 06 and 0 5 ug ml Susceptible by MGIT AST however resistance by Welpak S E coli numbering system for fi subunit of the RNA polymerase 23d Z ZEA Musser rpoB 507 533 27 81 bp RFP 95
Download Pdf Manuals
Related Search